Table 2.
Demographic subgroup composition of clinical trial participants with data from Drug Trials Snapshots for select oncology drugs approved between 2014 and 2017
| Demographic subgroup | % Participants | |||
|---|---|---|---|---|
| Breast cancer (n = 833) | Colorectal cancer (n = 800) | NSCLC (n = 1,979) | All cancers (n = 3,612) | |
| Race | ||||
| White | 84 | 58 | 71 | 71 |
| Black | 2 | 1 | 1 | 1 |
| Asian | 7 | 35 | 23 | 22 |
| AI‐AN | 0.1 | 0.1 | 0.1 | |
| NH‐OPI | 0.1 | 0.1 | 0.1 | |
| Other | 3 | 5 | 3 | |
| Multi | 0.1 | 0.03 | ||
| Sexa | ||||
| Female | 100 | 39 | 37 | 52 |
| Male | 61 | 63 | 48 | |
| Agea | ||||
| 17–64 years | 56 | 56 | 65 | 61 |
| ≥65 years | 44 | 44 | 35 | 39 |
Includes data from clinical trial participants listed in Drug Trials Snapshots from pivotal and supportive trials for non‐small cell lung cancer (NSCLC), colorectal cancer, or breast cancers for select oncology drugs approved between May 2014 and June 2017. Data for race or ethnicity listed as Unknown/Not reported is not included in the Table.
AI‐AN, American Indian or Native Alaskan; Multi, multiracial; NH‐OPI, Native Hawaiian or Other Pacific Islanders.
Sex and age information missing for 2 and 81 subjects, respectively (these subjects were excluded in respective demographic subgroup analysis).